Last modified: 22 May 2019 17:07
The will comprise lectures, tutorials and seminars. The curriculum will provide an in-depth look at pharmacovigilance, communication with regulators and the public using examples from both first and third world countries and will include detection of adverse drug reactions; causality assessment; prevention of adverse drug reactions including correct prescribing, prevention of drug errors and promotion of rational drug use; and communication of risk-benefit information to the general public. It will also include an introduction to the commercialisation of scientific ideas in the form of Bio-Business covering the pharma industry, spin out companies, IPR and finance.
|Session||Second Sub Session||Credit Points||15 credits (7.5 ECTS credits)|
Information on contact teaching time is available from the course guide.
2000 word essay on pharmacovigilance (50%); 500 word writing for the layman (20%); Presentation on a business model (30%).
There are no assessments for this course.